Johnson & Johnson has developed a single dose of vaccine to prevent coronavirus infection. This means that unlike other vaccines, it does not require two doses. After testing, officials at the U.S. Drug Enforcement Administration said the single-dose vaccine was also quite safe and effective.
This recognition would pave the way for Johnson’s approval of the vaccine in the United States. It will probably be approved in a few days. In that case, it will be the third vaccine to be approved in the country. It will be a cost-effective alternative to Pfizer and Modern Ticker. And it can be stored at the normal temperature of the refrigerator; No need for freezer.
Johnson & Johnson said it plans to deliver 20 million doses of the vaccine by next month. They have taken up the plan under an agreement with the United States to supply 100 million doses of vaccine by next June.
Earlier, Johnson & Johnson released the results of the vaccine’s effectiveness last month. According to Jensen, a Belgian-based company that owns a large pharmaceutical company, the vaccine is highly effective in treating serious illnesses, according to the data it has received.
Ghana has received the first vaccine under the CoVAX program adopted by the World Health Organization (WHO) to ensure corona vaccination in developing and least developed countries around the world. At such a time, US drug experts confirmed that Johnson’s vaccine was safe and effective.
Janssen has submitted data to the US Food and Drug Administration (FDA) on the effectiveness of their own vaccines. At the end of the review, the FDA released a more detailed document on the effectiveness of this vaccine. The drug regulator concluded that Johnson’s vaccine was effective in both coronary heart disease and coronary heart disease.
Johnson & Johnson’s ticker trials in the United States, South Africa, and Brazil have shown that it is ‘highly similar’ in acute corona infections. However, overall security has been less effective in South Africa and Brazil than in the United States. New strains of the virus are seen as influential in both countries.
Data show that Johnson’s vaccine is more than 75 percent effective in preventing serious illness. However, the overall effectiveness is 6 percent. This overall condition also includes moderate to severe illness. The condition of at least 28 days after vaccination has also been taken into consideration here.
Needless to say, none of those who took part in Johnson’s vaccination trial died or were hospitalized 28 days after the vaccination.
A committee of US pharmacologists will meet tomorrow, Friday. They will meet to make recommendations on whether the FDA should approve Johnson’s vaccine.
It will be a cost-effective alternative to Pfizer and Modern Ticker. And it can be stored at the normal temperature of the refrigerator; No need for freezer.
A White House official said they expect Johnson to receive at least 30 million doses of the vaccine next week. In that case, it must be approved by the FDA on an urgent basis.
Johnson & Johnson said it plans to deliver 20 million doses of the vaccine by next month. They have taken up the plan under an agreement with the United States to supply 100 million doses of vaccine by next June.
Experts say that while two doses of Pfizer and Modern vaccines are needed to prevent corona, Johnson’s vaccine will not require just one dose; On the contrary, the benefits of its effectiveness will be compounded by the fact that fewer medical personnel will be employed for vaccination.
More than six and a half million people in the United States have already been vaccinated against coronavirus. At present about 13 lakh people are being vaccinated daily. Over the past few weeks, the country has seen fewer new patients, hospital admissions and deaths from Covid-19. But top health experts warn that the coronavirus mutation is still a threat to this progress.
